Infliximab
- CAS NO.：170277-31-3
- Molecular Weight: 0
- MDL number: MFCD06795259
- Update Date: 2026-07-27 17:00:41
What is Infliximab?
The Uses of Infliximab
Infliximab targets the transcription factor NF-κB with harmine and related compounds for treatment of cancers and inflammatory diseases and combination with other agents
Properties of Infliximab
| storage temp. | Store at -30°C |
| form | Solid |
| color | White to off-white |
Safety information for Infliximab
Computed Descriptors for Infliximab
New Products
2-Bromo-4-hydroxypyridine Dibenzoyl-L-tartaric acid Anhydrous (Resolution Reagent) Dibenzo[b,f][1,4]thiazepin-11(10H)-one 1,2,3,9-Tetrahydro-9-Methyl-4H-Carbazole-4-One Cis-Tosylate 1-(4-methoxyphenyl)-4-(4-Nitrophenyl)Piperazine (IT-1) 1-aminocyclobutanecarbonitrile hydrochloride AMINO-O-TOLYL-ACETIC ACID 1-Aminocyclobutanecarboxylic Acid Hydrochloride AMINO(2-BROMOPHENYL)ACETIC ACID 6-BROMOTETRAZOLO[1,5-A]PYRIDINE 3-Oxocyclobutanecarboxylic acid METHANOL-D1(OD) TERTIARY BUTANOL-D9 N-ETHYL-D5-AMINE HYDROCHLORIDE BENZOIC ACID-D CHLOROFORM-D TOLUENE-D3 2-(2-Bromophenyl)ethanol Boc-D-Glu(OMe)-OMe 2,5 Dibromopyridine Ethyl 4-hydroxy-3-oxobutanoate Dimethyl (2S)-2-((tert-butoxycarbonyl)amino)-4-(cyanomethyl)pentanedioate 1-(3-Chlorophenyl)piperazine hydrochlorideRelated products of tetrahydrofuran
You may like
-
Infliximab CAS 170277-31-3View Details
170277-31-3 -
Infliximab BRP CAS 170277-31-3View Details
170277-31-3 -
254762-66-8 AMINO(2-BROMOPHENYL)ACETIC ACID 98+View Details
254762-66-8 -
23716-23-1 98+View Details
23716-23-1 -
6-BROMOTETRAZOLO[1,5-A]PYRIDINE 98+View Details
5799-75-7 -
254762-66-8 AMINO(2-BROMOPHENYL)ACETIC ACID 98+View Details
254762-66-8 -
23716-23-1 98+View Details
23716-23-1 -
6-BROMOTETRAZOLO[1,5-A]PYRIDINE 98+View Details
5799-75-7
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.